Glass Pharms, a leading UK-based medical cannabis cultivation company, is pleased to announce the appointment of Adam George as Chairman, effective as of December 1st, 2024.
Adam brings with him over 13 years of experience in the pharmaceutical cannabis industry, having previously held positions such as CFO and UK managing director at GW Pharmaceuticals. His extensive knowledge and expertise in this field will be instrumental in supporting Glass Pharms’ mission to provide high quality pharmaceutical cannabis products to patients in the UK.
James Duckenfield, Glass Pharms’ chief executive, expressed his enthusiasm for the new addition to the board, stating, “We are delighted that Adam has joined the team. His experience and expertise will be invaluable as we continue to strive towards our goal of providing reliable and high-quality cannabis-based medicines to patients in the UK.”
Adam George left GW Pharmaceuticals, now known as Jazz Pharmaceuticals, in 2020 and has since been involved in various businesses focused on developing medicines derived from natural sources, including plants and fungi.
In his statement, Adam said, “I am thrilled to be joining Glass Pharms at such an exciting time. With a world-class cultivation facility and a dedicated team, the company is well-positioned to meet the increasing demand for high-quality, UK-produced cannabis-based medicines.”
Glass Pharms is a licensed cultivator of cannabis, exclusively for the medical supply chain, in the UK. The company was founded with the aim of providing patients with a dependable supply of high-quality, UK-produced cannabis-based medicines at an affordable price. With a talented growing team and a unique patent-pending continuous cultivation system, Glass Pharms is able to produce a consistent supply of pharmaceutical-grade cannabis. This innovative system uses automation and climate chambers to simulate a full growing year in just 12 weeks, using only 40% of the power required by traditional indoor growing facilities. Additionally, the company is committed to using off-grid green energy to power its operations.
For more information about Glass Pharms, please visit their website at https://glasspharms.com/. For media inquiries, please contact Mark Heley at info@glasspharms.com.
This news release was distributed by https://pressat.co.uk/.
